CATALOGO DEI PRODOTTI DELLA RICERCA

CAMINATI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.408
NA - Nord America 4.726
AS - Asia 4.432
SA - Sud America 734
AF - Africa 144
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 4
Totale 15.453
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.598
RU - Federazione Russa 2.752
SG - Singapore 1.897
CN - Cina 1.200
IT - Italia 679
BR - Brasile 584
HK - Hong Kong 520
GB - Regno Unito 425
VN - Vietnam 347
FR - Francia 321
DE - Germania 317
IE - Irlanda 291
SE - Svezia 260
KR - Corea 149
FI - Finlandia 115
CA - Canada 65
IN - India 62
JP - Giappone 60
AR - Argentina 54
MX - Messico 49
ID - Indonesia 46
NL - Olanda 44
PL - Polonia 43
ES - Italia 40
BJ - Benin 37
ZA - Sudafrica 37
BD - Bangladesh 36
TG - Togo 36
TR - Turchia 29
AT - Austria 24
UA - Ucraina 24
CO - Colombia 23
EC - Ecuador 21
BE - Belgio 19
VE - Venezuela 16
CL - Cile 13
PY - Paraguay 12
IQ - Iraq 11
LT - Lituania 11
MA - Marocco 9
SA - Arabia Saudita 9
PK - Pakistan 8
AZ - Azerbaigian 7
NO - Norvegia 7
UZ - Uzbekistan 7
AE - Emirati Arabi Uniti 6
BG - Bulgaria 6
CH - Svizzera 6
KE - Kenya 6
PE - Perù 6
JO - Giordania 5
EG - Egitto 4
IL - Israele 4
JM - Giamaica 4
LV - Lettonia 4
OM - Oman 4
UY - Uruguay 4
BY - Bielorussia 3
CZ - Repubblica Ceca 3
LB - Libano 3
NP - Nepal 3
SN - Senegal 3
AU - Australia 2
CR - Costa Rica 2
DM - Dominica 2
EU - Europa 2
GH - Ghana 2
KG - Kirghizistan 2
MG - Madagascar 2
MY - Malesia 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TJ - Tagikistan 2
TL - Timor Orientale 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BZ - Belize 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
GM - Gambi 1
GR - Grecia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
KI - Kiribati 1
KZ - Kazakistan 1
Totale 15.441
Salva come PNG Salva come JPEG
Città #
Moscow 905
Dallas 756
Singapore 734
Chandler 603
Hong Kong 514
Ashburn 426
New York 310
Beijing 289
Dublin 286
Southend 245
Los Angeles 133
Verona 132
Lawrence 120
Princeton 120
Ho Chi Minh City 102
Sindelfingen 102
Wilmington 95
The Dalles 93
Jacksonville 82
Munich 79
Buffalo 76
Hanoi 73
Redondo Beach 71
Jinan 64
Columbus 62
London 61
Ann Arbor 56
São Paulo 55
Helsinki 53
Tokyo 52
Milan 51
Nanjing 48
Hebei 46
Woodbridge 46
Shenyang 44
Guangzhou 42
Rome 42
Redwood City 41
Redmond 40
Turku 40
Warsaw 40
Cotonou 37
Lomé 35
Zhengzhou 32
Boardman 31
Santa Clara 30
Amsterdam 29
Brooklyn 29
Dong Ket 29
Bologna 28
Denver 27
Haikou 27
Seattle 27
Chennai 25
Johannesburg 25
Ningbo 25
Nuremberg 25
Houston 23
Jakarta 23
Poplar 23
Tianjin 22
Changsha 21
Norwalk 21
San Francisco 21
Kent 20
Stockholm 20
Toronto 20
Council Bluffs 19
Boston 18
Montreal 18
Taiyuan 18
Atlanta 16
Brussels 16
Haiphong 16
Mexico City 16
Rio de Janeiro 16
Taizhou 16
Falkenstein 15
Hangzhou 15
Phoenix 15
Frankfurt am Main 14
Orem 14
Curitiba 13
Nanchang 13
Naples 13
Jiaxing 12
Lanzhou 12
Lappeenranta 12
Padova 12
Ankara 11
Chicago 11
Da Nang 11
Porto Alegre 11
Querétaro 11
Quito 11
Belo Horizonte 9
Brasília 9
Brescia 9
Falls Church 9
Palermo 9
Totale 8.344
Salva come PNG Salva come JPEG
Nome #
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management 369
Safety of Biologic Therapies for Severe Asthma: An Analysis of Adverse Reactions Reported in the WHO Pharmacovigilance Database 179
Fatal asthma; is it still an epidemic? 166
Allergic rhinitis: pharmacotherapy in pregnancy and old age 157
Asthmatic patients in COVID-19 outbreak: Few cases despite many cases 157
Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience 144
Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study 140
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 140
Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis 139
Adverse reaction to local anaesthetics: Is it always allergy? 138
Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain 137
Thunderstorm Asthma: A Critical Appraisal Based on Clinical Practice 131
Biologics for Eosinophilic Granulomatosis with Polyangiitis: one size does not fit all 131
Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges? 130
Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma 130
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 128
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis 128
Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved? 126
Asthma and anaphylaxis 124
COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control 124
Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy 123
Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19 123
Periostin: The bone and beyond 122
Anaphylaxis and intimate behaviour 121
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 121
Evaluation of asthma control in the pharmacy: an Italian cross-sectional study 119
Anxiety and Depression Effects During Drug Provocation Test 119
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma 117
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase 115
Low‑dose anti‑IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance 115
Allergy and Sexual Behaviours: an Update 114
Allergen-specific immunotherapy and COVID-19: What happened? 111
ALLERGY AND CORONAVIRUS DISEASE (COVID-19) INTERNATIONAL SURVEY: REAL-LIFE DATA FROM THE ALLERGY COMMUNITY DURING THE PANDEMIC 111
Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship? 110
Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders 110
Biologics and global burden of asthma: A worldwide portrait and a call for action 110
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic 108
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 107
[Fractional exhaled nitric oxide measurement during specific inhalation challenge tests] 107
COPD prevalence in a north-eastern Italian general population 106
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response 105
Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety 105
The potential role of local pharmacies to assess asthma control: an Italian cross-sectional study 105
Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? 104
Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series 103
Uncontrolled Asthma: Unmet Needs in the Management of Patients 102
What lies beyond Asthma Control Test: Suggestions for clinical practice 100
Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach 99
Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study 98
Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics 98
Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach 96
Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia 96
Asthma management among different specialists: results from a national Italian survey 94
Omalizumab management beyond clinical trials: the added value of a network model 93
Relevance of TH2 markers in the assessment and therapeutic management of severe allergic asthma: A real-life perspective 93
Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report 92
Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma: reply 92
Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life 91
Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort 90
Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy 89
Adherence to Intranasal Steroids in Chronic Rhinosinusitis with Nasal Polyposis Prior to and during Biologic Therapy: A Neglected Matter 87
SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma 87
Towards precision medicine: The application of omics technologies in asthma management 87
Biologic Therapy in a Patient with Asthma and Nasal Polyps 87
One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response 87
Aspergillus fumigatus and personalized medicine: Toward a clinically reliable algorithm 86
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis 86
Profiling blood hypereosinophilia in patients on dupilumab treatment for respiratory conditions: a real-life snapshot 84
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly 84
A hierarchical cluster analysis of the psycological impact of the COVID-19 pandemic on Italian severe asthma patients 83
Relevance of Smoking Habit in Severe Asthma Patients: Evidence from the Severe Asthma Network in Italy (SANI) Registry 83
Targeting eosinophils: severe asthma and beyond 83
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 83
Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in β-Thalassemia: additional dose role 81
Diagnosis and Management of Allergic Rhinitis in Asthmatic Children 81
Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice 80
Serum periostin during omalizumab therapy in asthma: A tool for patient selection and treatment evaluation 80
Severe refractory asthma: current treatment options and ongoing research 80
Component resolved diagnosis (CRD): how much is it presently used by Italian allergists? 80
Oral health in asthmatic patients: a review: Asthma and its therapy may impact on oral health 80
Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps 80
Diagnosis, management and therapeutic options for eosinophilic esophagitis 79
Effect of α1 Antitrypsin Deficiency on Lung Volume Decline in Severe Asthmatic Patients Undergoing Biologic Therapy 79
Serum biomarkers of remodeling in severe asthma with fixed airway obstruction and the potential role of KL-6 78
One year of mepolizumab. Efficacy and safety in real-life in Italy 78
How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients 78
The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors 77
Biologic Therapy in a Patient with Asthma and Nasal Polyps 77
BCG vaccination and COVID-19: Much ado about nothing? 77
Type 2 immunity in asthma 76
Asthma management among allergists in Italy: results from a survey 76
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 76
Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity 76
Immunoglobulin free light chains in severe asthma patient: Could they be a new biomarker? 76
Occupational rhinitis to sodium alendronate 75
Quality of life in patients with food allergy 75
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence 75
Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective 73
Italian study on buckwheat allergy: prevalence and clinical features of buckwheat-sensitized patients in Italy 73
Sex in Respiratory and Skin Allergies 73
Totale 10.448
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.758
article - articoli 64.538
book - libri 0
conference - conferenze 220
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 129.516
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021389 0 0 0 0 144 77 17 23 20 9 45 54
2021/2022714 94 176 15 43 15 14 7 50 50 12 58 180
2022/20231.926 145 138 223 221 217 452 43 106 240 12 80 49
2023/20241.487 57 102 124 196 117 345 110 61 19 62 194 100
2024/20253.674 177 215 155 507 136 92 115 346 581 266 303 781
2025/20266.576 813 706 774 1.892 2.391 0 0 0 0 0 0 0
Totale 15.721